Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | May 20, 2026 | May 22, 2026 |
| BeOne Medicines Ltd.ONC · Entity 2168 | Director | June 11, 2026 | June 15, 2026 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,446 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 671 · Balance 1,446 F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $298.48 · Expires 2036-05-20 | Direct | 1,441 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 1,441 · Balance 1,441 F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
BeOne Medicines Ltd.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 46,306 |
Reported balance
After 2026-06-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 18,980 · Balance 46,306 F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.
Vaxcyte, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,699 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 2,194 · Balance 4,699 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.56 · Expires 2036-06-15 | Direct | 11,034 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 11,034 · Balance 11,034 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PFIZER INC
Report date October 31, 2013 · Filed November 04, 2013
Section 16 reporting ended · disclosed 2013-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 17,166 |
Reported balance
After 2013-10-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2013-10-31 · Grant · Acquired 51 · Balance 17,166 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 20:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 11,034 | $0.00 Strike: $49.56 | $0.00 |
DisclosureSEC source: 0001508518-26-000005 · wk-form4_1781641242.xml · derivative · entry 2 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,034 Underlying: Common Stock · 11,034 shares Expires 2036-06-15 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001508518-26-000005 · wk-form4_1781641242.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,699 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:51 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantOrdinary Shares | 18,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001508518-26-000003 · wk-form4_1781560262.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,306 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (Right to Buy) · Derivative | 1,441 | $0.00 Strike: $298.48 | $0.00 |
DisclosureSEC source: 0001178670-26-000036 · form4.xml · derivative · entry 2 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,441 Underlying: Common Stock · 1,441 shares Expires 2036-05-20 F2 · derivative.exercise_date: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 671 | $0.00 | $0.00 |
DisclosureSEC source: 0001178670-26-000036 · form4.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,446 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 6,750 | $0.00 Strike: $48.04 | $0.00 |
DisclosureSEC source: 0001508518-26-000002 · wk-form4_1768601306.xml · derivative · entry 2 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 6,750 shares Expires 2035-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 22:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 1,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001508518-26-000002 · wk-form4_1768601306.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,505 F1 · acquired: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 5,807 | $0.00 Strike: $34.46 | $0.00 |
DisclosureSEC source: 0001508518-25-000008 · wk-form4_1750112658.xml · derivative · entry 2 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,807 Underlying: Common Stock · 5,807 shares Expires 2026-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 1,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001508518-25-000008 · wk-form4_1750112658.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,148 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 21, 2025 Filed May 22, 2025 23:46 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 22,750 | $0.00 Strike: $18.19 | $0.00 |
DisclosureSEC source: 0001651308-25-000089 · wk-form4_1747957555.xml · derivative · entry 2 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,750 Underlying: Ordinary Shares · 22,750 shares Expires 2035-05-20 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 21, 2025 Filed May 22, 2025 23:46 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 10,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000089 · wk-form4_1747957555.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,326 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 1,558 | $0.00 Strike: $258.35 | $0.00 |
DisclosureSEC source: 0001735276-25-000066 · edgardoc.xml · derivative · entry 2 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,558 Underlying: Common Stock · 1,558 shares Expires 2035-05-08 F2 · derivative.exercise_date: The stock option vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000066 · edgardoc.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 775 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:28 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 40,113 | $0.00 Strike: $35.24 | $0.00 |
DisclosureSEC source: 0001649094-25-000062 · wk-form4_1746217718.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,113 Underlying: Common Stock · 40,113 shares Expires 2035-05-01 F1 · derivative.exercise_date: Option shall vest over 36 months, 1/3 of which will vest on May 1, 2026 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:01 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 34,151 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001651308-24-000064 · wk-form4_1717794089.xml · derivative · entry 2 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,151 Underlying: Ordinary Shares · 34,151 shares Expires 2034-06-04 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:01 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 16,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-24-000064 · wk-form4_1717794089.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,341 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 5,228 | $0.00 Strike: $151.22 | $0.00 |
DisclosureSEC source: 0001735276-24-000051 · edgardoc.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,228 Underlying: Common Stock · 5,228 shares Expires 2034-05-16 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 22:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 27,794 | $0.00 Strike: $12.74 | $0.00 |
DisclosureSEC source: 0001651308-24-000018 · wk-form4_1709591065.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,794 Underlying: Ordinary Shares · 27,794 shares Expires 2034-02-28 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 3,454 | $0.00 Strike: $189.87 | $0.00 |
DisclosureSEC source: 0001735276-23-000066 · edgardoc.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,454 Underlying: Common Stock · 3,454 shares Expires 2033-05-18 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-22-000054 · edgardoc.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 4,032 | $0.00 Strike: $171.95 | $0.00 |
DisclosureSEC source: 0001735276-21-000072 · edgardoc.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Underlying: Common Stock · 4,032 shares Expires 2031-07-14 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:35 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 8,612 | $0.00 Strike: $114.78 | $0.00 |
DisclosureSEC source: 0001735276-20-000039 · edgardoc.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,612 Underlying: Common Stock · 8,612 shares Expires 2030-03-02 F1 · derivative.exercise_date: The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant. Read SEC document |
| October 31, 2013 Filed Nov 4, 2013 20:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 51 | $30.69 | $1,565.19 |
DisclosureSEC source: 0001225208-13-022783 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,166 Underlying: Common Stock · 51 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 74 | $29.16 | $2,157.84 |
DisclosureSEC source: 0001225208-13-021904 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,115 Underlying: Common Stock · 74 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2013 Filed Oct 2, 2013 14:01 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 51 | $28.73 | $1,465.23 |
DisclosureSEC source: 0001225208-13-020973 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,041 Underlying: Common Stock · 51 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 13, 2013 Filed Sep 17, 2013 16:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 65 | $28.51 | $1,853.15 |
DisclosureSEC source: 0001225208-13-020061 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,990 Underlying: Common Stock · 65 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 30, 2013 Filed Sep 4, 2013 14:15 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 69 | $28.21 | $1,946.49 |
DisclosureSEC source: 0001225208-13-018976 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,925 Underlying: Common Stock · 69 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2013 Filed Aug 16, 2013 19:01 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 67 | $28.80 | $1,929.60 |
DisclosureSEC source: 0001225208-13-017996 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,856 Underlying: Common Stock · 67 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2013 Filed Aug 1, 2013 21:49 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 198 | $29.23 | $5,787.54 |
DisclosureSEC source: 0001225208-13-017090 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,789 Underlying: Common Stock · 198 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2013 Filed Jul 16, 2013 22:29 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 63 | $28.79 | $1,813.77 |
DisclosureSEC source: 0001225208-13-016256 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,591 Underlying: Common Stock · 63 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 28, 2013 Filed Jul 2, 2013 13:48 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 68 | $28.01 | $1,904.68 |
DisclosureSEC source: 0001225208-13-015227 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,528 Underlying: Common Stock · 68 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 14, 2013 Filed Jun 18, 2013 17:07 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 58 | $29.09 | $1,687.22 |
DisclosureSEC source: 0001225208-13-014496 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,460 Underlying: Common Stock · 58 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2013 Filed Jun 3, 2013 22:28 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 81 | $27.23 | $2,205.63 |
DisclosureSEC source: 0001225208-13-013697 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,402 Underlying: Common Stock · 81 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2013 Filed May 16, 2013 23:22 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 193 | $29.56 | $5,705.08 |
DisclosureSEC source: 0001225208-13-012560 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,321 Underlying: Common Stock · 193 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2013 Filed May 1, 2013 22:20 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 64 | $29.07 | $1,860.48 |
DisclosureSEC source: 0001225208-13-010912 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,128 Underlying: Common Stock · 64 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2013 Filed Apr 17, 2013 12:05 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 33 | $30.45 | $1,004.85 |
DisclosureSEC source: 0001225208-13-010051 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,064 Underlying: Common Stock · 33 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2013 Filed Mar 18, 2013 21:44 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 1,751 | $28.02 | $49,063.02 |
DisclosureSEC source: 0001225208-13-007868 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,033 Underlying: Common Stock · 1,751 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 56,064 | $28.14 | $1,577,640.96 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 8 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,076 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 13,970 | $28.15 | $393,255.50 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 7 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,140 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 13,800 | $28.11 | $387,918.00 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 6 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,110 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 13,000 | $28.12 | $365,560.00 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 5 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,910 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 9,500 | $28.13 | $267,235.00 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 4 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,910 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 4,100 | $28.17 | $115,497.00 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 3 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,410 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 2,430 | $28.16 | $68,428.80 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 2 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,510 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 500 | $28.10 | $14,050.00 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,940 Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 127,971 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · derivative · entry 9 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,971 Underlying: Common Stock · 127,971 shares Expires 2020-02-28 F9 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F9 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 154,185 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · derivative · entry 8 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,185 Underlying: Common Stock · 154,185 shares Expires 2018-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 40,629 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · derivative · entry 7 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,629 shares Expires 2013-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Dividend equivalents are paid on these stock appreciation rights at the time of settlement. F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 41,196 | $27.37 | $1,127,534.52 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · nonDerivative · entry 5 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,440 F5 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 24,743 | $27.37 | $677,215.91 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · nonDerivative · entry 4 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,636 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.